Session 5: Management of Treatment Lines Throughout the Course of CLL

Co-Chair(s)

• 

  Barbara Eichhorst, MD

  Associate Professor, Consultant Hematologist
  Department I of Internal Medicine, University Hospital of Cologne
  Cologne, Germany
• WW

  William G. Wierda, MD, PhD

  Professor of Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

Presentations:

• 08:15 - 08:35 CEST

  Goals of Treatment Aligning with Continuum of Disease and Impact of First-Line Choices
  

  Speaker: Jennifer A. Woyach, MD – Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
• 08:35 - 08:55 CEST

  Individualizing First-Line Treatment Choice Based on Patient and Disease Characteristics
  

  Speaker: Nitin Jain, MD – The University of Texas MD Anderson Cancer Center
• 08:55 - 09:10 CEST

  Panel Discussion With Interactivity and Audience Q&A
• 09:10 - 09:20 CEST

  NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
  

  Primary Author / Presenter: Moritz Fürstenau, MD – Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
• 09:20 - 09:25 CEST

  Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL
  

  Primary Author / Presenter: Thomas Chatzikonstantinou, MD – Institute of Applied Biosciences, Centre for Research and Technology Hellas